Asston Pharmaceuticals Launches Landmark IPO
Asston Pharmaceuticals, based in Navi Mumbai, launches its IPO on July 09, 2025, aiming to raise ₹27.56 Crores. Funds will bolster capital expenditure, debt repayment, and corporate growth. The issue follows a 100% book-building process, with shares listed on BSE SME platform. Revenue for FY25 was ₹2,503.92 Lakhs.
- Country:
- India
Mumbai (Maharashtra) [India], July 7: Asston Pharmaceuticals, headquartered in Navi Mumbai, will open its IPO on July 09, 2025, targeting a ₹27.56 Crore issue on the BSE SME platform.
The IPO, utilizing a 100% book-building process as per SEBI guidelines, allocates shares among QIBs, non-institutional investors, and retail individuals. Funds will enhance capital expenditure, manage working capital, repay debts, and support general corporate aims.
Dr. Ashish Narayan Sakalkar, Managing Director, emphasized the IPO as a major growth step, citing plans for infrastructure investments and expanding their presence in the pharmaceutical sector. FY25 saw the company record ₹2,503.92 Lakhs in revenue, showcasing its financial resilience.
(With inputs from agencies.)
ALSO READ
SEBI Proposes Overhaul of Market Infrastructure Governance
Sebi Proposes Governance Overhaul for Market Infrastructure Institutions
Glenmark Pharmaceuticals Launches Tevimbra: A Milestone in Cancer Treatment in India
BSE Shares Recover Despite SEBI's Penalty Over Disclosures Access
Sebi Fines BSE Rs 25 Lakh for Failing to Ensure Equal Access to Corporate Disclosures
Google News